- Report
- March 2024
- 191 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- March 2024
- 195 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- January 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- November 2023
- 148 Pages
Global
From €2398EUR$2,499USD£2,065GBP
- Report
- November 2023
- 170 Pages
Global
€4793EUR$4,995USD£4,128GBP
- Report
- December 2018
- 174 Pages
Global
From €1319EUR$1,375USD£1,136GBP
€2639EUR$2,750USD£2,273GBP
- Report
- January 2022
- 111 Pages
Global
From €4558EUR$4,750USD£3,925GBP
- Report
- May 2023
- 91 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Report
- April 2023
- 147 Pages
Global
From €5756EUR$5,999USD£4,958GBP
- Book
- April 2022
- 656 Pages
Global
The Antitumor Antibiotic market is a subset of the Oncology Drugs market, which focuses on the development and sale of drugs used to treat cancer. Antitumor antibiotics are a type of chemotherapy drug that works by killing cancer cells or stopping them from growing and dividing. These drugs are typically administered intravenously or orally, and can be used alone or in combination with other treatments. They are used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Antitumor Antibiotic market is highly competitive, with many companies vying for market share. Some of the major players in the market include Pfizer, Merck, Bristol-Myers Squibb, AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to improve the efficacy of their products and gain a competitive edge. Show Less Read more